Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$4.08
−$0.14 · -3.32%
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Previous close
$4.08
−$0.14 · -3.32%
After-hours
$4.0897
+$0.0097 · +0.24%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Day range
Current $4.08
52-week range
Current $4.08
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
47
Fair Value
Sentiment
61
Bullish
Risk
72
High Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Day range
Current $4.08
52-week range
Current $4.08
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 20.6M USD | 3.75M USD | 140.14M USD | 5.09M USD | 13.16M USD |
| Cost of goods sold | — | — | 15.62M USD | 628K USD | 312K USD |
| Gross profit | 20.6M USD | 3.75M USD | 124.52M USD | 4.46M USD | 12.85M USD |
| Research and development | 22.28M USD | 26.41M USD | 30.93M USD | 27.26M USD | 23.77M USD |
| Selling, general, and administrative | 14.4M USD | 14.46M USD | 20.92M USD | 62.96M USD | 49.92M USD |
| Operating expenses | 36.68M USD | 40.86M USD | 51.85M USD | 90.22M USD | 73.69M USD |
| Interest income | 2.18M USD | 4.29M USD | 3.95M USD | 1.42M USD | 24K USD |
| Interest expense | 173K USD | 2.55M USD | 6.12M USD | 6.79M USD | 3.96M USD |
| Depreciation and amortization | 312K USD | 1.73M USD | 580K USD | 606K USD | 379K USD |
| Operating income | −16.07M USD | −37.12M USD | 72.67M USD | −85.76M USD | −60.84M USD |
| Net income | −8.61M USD | −21.29M USD | 67.04M USD | −62.81M USD | −32.87M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
